Drug intelligence / Profile preview

OXM-001

Development stage: Preclinical
Lead developer: Nordic Bioscience
Modality: Peptides
Administration: Subcutaneous

Overview

OXM-001 is a novel, long-acting oxyntomodulin analogue developed by Nordic Bioscience and its subsidiary KeyBioscience. It acts as a dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). In preclinical models of diet-induced obesity, OXM-001 has demonstrated robust efficacy in reducing body weight, lowering cumulative food intake, and improving glucose tolerance. It has shown superior acute weight-loss efficacy compared to other dual agonists like cotadutide (MEDI0382).

Targets

GLP1R (GLP-1R)GCGR (Glucagon receptor)

Beyond the preview

Go deeper on OXM-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OXM-001.